# N4 Pharma collaborates with SRI International to combine Nuvec and FOX Three MGS technology

- Link: https://www.directorstalkinterviews.com/n4-pharma-collaborates-with-sri-international-to-combine-nuvec-and-fox-three-mgs-technology/4121153593
- Published: 2024-04-25T08:21:46+01:00
- Author: Amilia Stone

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system designed to carry nucleotides to be developed as cancer
treatments and vaccines, has announced that it has entered into a research collaboration
agreement with SRI International, an independent nonprofit research institute based
in Silicon Valley, California to combine Nuvec® with SRI’s proprietary FOX Three
Molecular Guidance System™ (MGS) with the aim of co-marketing the resultant combined
technology.

Under the Agreement, the Company will collaborate with SRI to perform research to
conjugate its MGS system to Nuvec® in order to increase intracellular delivery to
specific target cells. On the back of the combined technology, N4 Pharma and SRI
will work collaboratively to develop and pursue new business opportunities.

SRI’s MGS technology is designed to overcome cellular barriers that prevent intracellular
delivery of large molecule biotherapeutics. The system uses proprietary technology
that enables the delivery of macromolecular payloads to the target cell and then
on to subcellular locations within those cells. SRI has developed a panel of 50 
MGSs targeted at a wide variety of cell types, both diseased and healthy.

SRI has demonstrated that the MGS technology can deliver more than a dozen types
of payloads – from functional enzymes, antibodies, and nucleic acids (including 
siRNA, ASOs, and DNA) to liposomes and nanoparticles – to targeted, intracellular
molecular-target locations previously considered unreachable, and therefore, untreatable.
For more information on MGS see: https://www.sri.com/platform/fox-three-molecular-
guidance-system-mgs/.

The SRI Biosciences division the Company will be working with integrates basic biomedical
research with drug and diagnostics discovery, and preclinical and clinical development.
The team has advanced more than 200 drugs to clinical trials, and 25 have reached
the market. The division is focused on novel platforms and programs in a variety
of therapeutic areas targeting high unmet medical needs.

> **Kathlynn Brown, President of SRI’s Bioscience Division, commented:**
> **“**We’re excited to work with N4 Pharma to advance nucleic acid therapies and
> expand the number of applications of their Nuvec nanoparticle technology using
> the FOX Three Platform. The key properties of Nuvec, including preventing enzymatic
> breakdown of nucleotides and large surface area allowing multiple copy number 
> of cargo, together with the targeting provided by MGS, may significantly enhance
> the use of nucleotide therapies. This partnership marks an exciting journey towards
> expanding treatment possibilities and transforming the landscape of biomedicine.”

> **Nigel Theobald, Chief Executive Officer of the Company, commented****:**
> _“_We are delighted to be working with SRI and to have entered into this collaboration
> agreement. Combining our technologies successfully will lead to working with major
> pharma companies in the fields of oncology and vaccines with the exciting potential
> to develop novel products.
> “SRI collaborates with a broad range of partners from small and virtual biotechnology
> companies to top ten pharmaceutical companies and other leading industry partners,
> which will give us unparalleled access to potential commercial partners on the
> back of any successful combined technology resulting from our research.
> This marks an exciting new chapter for N4 Pharma and I look forward to providing
> further updates as the research work progresses, as well as on our other work 
> streams such as oral applications of Nuvec® and the development of ECP105 for 
> an orphan indication with Nanogenics.”

Share on:
